AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06475040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
Study NCT06379282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: Exercise training only
Study NCT06379282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXE+ Nutritional Guidance
Description: Exercise Training + Nutritional Guidance
Study NCT05574465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High resolution solid state manometry
Description: The use of esophageal manometry device during removal of endotracheal tube by anesthesia
Study NCT06462378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: External beam proton therapy combined with standard cisplatin and brachytherapy
Study NCT05574361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic Machine Perfusion
Description: Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
Study NCT04931966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: block
Description: Adductor canal block
Study NCT04931966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: adductor canal block bupivacain
Study NCT04931966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block plus IPACK Block
Description: Adductor Canal Block plus IPACK Block using bupivacaine
Study NCT04931966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor Canal Block plus PAI Block
Description: Adductor Canal Block plus PAI Block using bupivacaine
Study NCT05178862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Description: Oral ibrexafungerp (SCY-078) as step-down therapy.
Study NCT05178862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral fluconazole (SCY-078) as step-down therapy.
Study NCT05178862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinocandin
Description: Intravenous echinocandin
Study NCT05178862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinocandin
Description: Intravenous echinocandin
Study NCT05849519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme I for Injection + conventional treatment
Description: The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
Study NCT05849519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional treatment
Description: The control group was treated with conventional treatment
Study NCT05325385 — intervention group
Intervention type: OTHER
Intervention: There are no interventions - this is a database study only
Description: There are no interventions - this is a database study only
Study NCT05201950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual simulation
Description: Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
Study NCT05201950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Team based in situ simulation
Description: In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
Study NCT06007053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
Study NCT06007053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
Study NCT05870891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Food
Study NCT05870891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Food
Study NCT03890029 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Training
Description: After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
Study NCT03890029 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
Study NCT05778734 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CM-PST
Description: CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
Study NCT05778734 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CM only
Description: CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
Study NCT06649110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTP
Description: LTP001
Study NCT06649110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05713136 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Test: Point-of-Care Testing
Description: Participants will be offered finger-stick point-of-care testing for HCV
Study NCT06175013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sérum PURIFIANT
Description: Application of Sérum PURIFIANT only, twice daily during 112 days
Study NCT06175013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sérum PURIFIANT in association Sérum BOOSTER
Description: Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
Study NCT05063110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Administration of 300 mg of ITACITINIB per os every day for 30 days.
Study NCT06061627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOT-CRT group
Description: In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP).
Study NCT06061627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiVP group
Description: Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
Study NCT06225323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours.
Study NCT06225323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours.
Study NCT06551818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SesZen-Bio Low Dose 1 (350 mg extract)
Description: Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral
Study NCT06551818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SesZen-Bio Low Dose 1 (150 mg liposomal)
Description: Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral
Study NCT06551818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SesZen-Bio High Dose 1 (500 mg extract)
Description: Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral
Study NCT06551818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral
Study NCT04409392 — intervention group
Intervention type: OTHER
Intervention: Prothestic joint infection due to Staphylococcus lugdunensis
Description: description of prosthetic joint infection with Staphylococcus lugdunensis
Study NCT06275256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
Study NCT06275256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind
Description: The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
Study NCT06757829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training and acupucnture like transcutanoeus electrical nerve stimulation
Description: sickle cell disease patients whose number will be 20 patients will be trained with IMT (threshold inspiratory muscle training) and treated with AC-tens. The number of sessions per week will be three sessions for IMT or AC-tens for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles. Also the session of AC-tens will be 45 minute on bilateral Ex-B1 acupoint. the parameters of AC-tens will be four hertz and 200 microsecond pulse duration.
Study NCT06757829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: sickle cell disease patients whose number will be 20 patients who will trained with IMT (threshold inspiratory muscle training). The number of sessions per week will be three sessions for IMT for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles.
Study NCT06757842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness in Students
Description: The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.
Study NCT06758115 — intervention group
Intervention type: PROCEDURE
Intervention: Tuina (Massage) Therapy
Description: Operation Method:~Correct abnormal joint alignment - Manipulatively realign the vertebral segments and pelvis affected by scoliosis.~Correct abnormal muscle function - After realigning the vertebral bodies to their normal position, stretch the corresponding tight and shortened muscles while strengthening the muscles that need to be lengthened.~Restore joint stability - After adjusting the vertebrae and muscles, instruct the patient to hold the corrected posture for at least 10 seconds, then relax for 10 seconds. Repeat this cycle 3-5 times.~Restore sensorimotor control - Provide appropriate movement disturbances to patients maintaining the corrected posture to enhance proprioception and motor memory in the corresponding muscles.~The total duration of the manipulation is 20-25 minutes. Treatment is performed twice a week for a total of 12 weeks.
Study NCT04446949 — intervention group
Intervention type: OTHER
Intervention: Register follow-up
Description: Number of adverse pregnancy outcomes
Study NCT06451107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific strength training with static neck stretching
Description: The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
Study NCT06451107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific Strength Training
Description: The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
Study NCT06284356 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy
Study NCT04739306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P42
Description: 2mg/0.05 mL by Intravitreal injection
Study NCT04739306 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: 2mg/0.05 mL by Intravitreal injection
Study NCT06758076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1 (ocufilcon D)
Description: 15 minutes of daily wear
Study NCT06758076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2 (somofilcon A)
Description: 15 minutes of daily wear
Study NCT05522231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib+sintilimab
Description: fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
Study NCT05522231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: axitinib / everolimus
Description: axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
Study NCT05522231 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fruquintinib
Description: fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
Study NCT04429893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulphate
Description: assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
Study NCT04429893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivicaine
Description: assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
Study NCT04429893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine
Description: assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
Study NCT06304246 — intervention group
Intervention type: OTHER
Intervention: Measurement Pain Threshold
Description: Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
Study NCT06304246 — intervention group
Intervention type: OTHER
Intervention: Measurement of Serum Asprosin
Description: Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Study NCT05145426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound
Description: Application of LIFU
Study NCT04628091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling on surgery day
Description: In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube.
Study NCT03127111 — intervention group
Intervention type: GENETIC
Intervention: Gene mutations analysis
Description: Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
Study NCT05562973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive three psilocybin sessions, at least two weeks apart.
Study NCT06092099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Description: The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
Study NCT05459922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable bright light therapy device
Description: Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
Study NCT05459922 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearable placebo light therapy device
Description: The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.